000756 新华制药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)5.0539.84911.44110.82610.417
总资产报酬率 ROA (%)2.8295.4326.0005.2714.833
投入资产回报率 ROIC (%)3.4636.6937.4226.6316.113

边际利润分析
销售毛利率 (%)19.17224.11429.52427.15427.037
营业利润率 (%)4.6116.3126.5996.3546.488
息税前利润/营业总收入 (%)4.8356.4476.7786.7157.228
净利润/营业总收入 (%)3.9475.7496.2485.6795.519

收益指标分析
经营活动净收益/利润总额(%)107.35098.566106.994102.27591.717
价值变动净收益/利润总额(%)1.9941.8431.7991.7731.903
营业外收支净额/利润总额(%)-1.897-0.134-0.356-1.045-1.034

偿债能力分析
流动比率 (X)1.3071.3331.3331.0941.101
速动比率 (X)0.8870.8780.8050.7110.690
资产负债率 (%)40.72442.15442.36547.37250.203
带息债务/全部投入资本 (%)27.85728.88728.63335.11224.727
股东权益/带息债务 (%)248.241235.109237.510175.807245.469
股东权益/负债合计 (%)139.037131.285129.703105.39094.215
利息保障倍数 (X)15.59344.95633.57815.7348.962

营运能力分析
应收账款周转天数 (天)37.71733.33932.46634.06228.494
存货周转天数 (天)62.36972.44679.60873.75480.926